Form 4: LMAT Director John Roush Acquires Shares via PSU Vesting

Lemaitre Vascular Director John Roush acquired 477 shares of common stock through the settlement of a Performance Share Unit award and dividend equivalent rights.

Summary

• John A. Roush, a Director of Lemaitre Vascular Inc. (LMAT), acquired 476 shares of common stock on February 26, 2026, through the settlement of a Performance Share Unit (PSU) award.
• The PSU award was granted on December 6, 2024, and vested 1/3 upon satisfaction of performance conditions on February 26, 2026.
• The remaining balance of the PSU award will vest in equal annual installments on the grant date anniversary over the next two years.
• An additional 1 share of common stock was acquired on February 26, 2026, upon the release of dividend equivalent rights, which were connected to the vesting of the PSU award.
• Following these transactions, John A. Roush directly beneficially owns 3,942 shares of common stock and indirectly owns 181 shares through his spouse.
• He also directly beneficially owns 2.8963 Dividend Equivalent Rights.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting a routine compensation transaction where a director increased their ownership through performance-based awards, indicating achieved performance conditions.

Positives

• Director John A. Roush increased his direct beneficial ownership in Lemaitre Vascular Inc. by 477 shares.
• The acquisition of shares stems from the successful vesting of a Performance Share Unit (PSU) award, indicating the achievement of performance conditions.
• The ongoing vesting schedule for the remaining PSU award provides a future incentive for the director.

Future Outlook

The remaining balance of the Performance Share Unit (PSU) award granted on December 6, 2024, is scheduled to vest in equal annual installments on the grant date anniversary over the next two years.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those related to equity compensation plans like PSUs, are common across the medical device industry. These filings typically reflect pre-scheduled compensation events rather than discretionary open-market purchases or sales, and are generally viewed as neutral unless they represent a significant shift in ownership or a deviation from established compensation practices.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) as a component of executive and director compensation is a standard practice in the medical device industry, aligning executive incentives with company performance. Companies like Medtronic (MDT) and Boston Scientific (BSX) also utilize similar long-term incentive structures.
• The vesting schedule, with an initial vesting upon performance condition satisfaction and subsequent annual installments, is a common design for such awards, promoting long-term retention and sustained performance.

Stakeholder Impact

• Shareholders: Director's increased ownership through performance-based awards may be viewed positively, aligning management interests with shareholder value creation.

Next Steps

• The balance of the Performance Share Unit (PSU) award will vest in equal annual installments on the grant date anniversary over the next two years.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction related to equity compensation. While it shows a director increasing their ownership, it does not represent a discretionary open-market purchase or sale that would typically signal a strong 'buy' or 'sell' opportunity. The event is expected and does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Lemaitre Vascular, LMAT, Insider Transaction, Form 4, Performance Share Unit, PSU, Stock Acquisition, Director Ownership, Equity Compensation, Dividend Equivalent Rights